Oral Prostacyclin Pathway Agents Used in PAH: A Targeted Literature Review

References

• Hassoun PM, Taichman DB. Pulmonary Arterial Hypertension. N Engl J Med. 2021;385(25):2361–2376. doi:10.1056/NEJMra2000348
   PubMed Web of Science ®Google Scholar
• Lai YC, Potoka KC, Champion HC, Mora AL, Gladwin MT. Pulmonary arterial hypertension: the clinical syndrome. Circ Res. 2014;115(1):115–130. doi:10.1161/CIRCRESAHA.115.301146
   PubMed Web of Science ®Google Scholar
• Austin ED, Kawut SM, Gladwin MT, Abman SH. Pulmonary hypertension: NHLBI workshop on the primary prevention of chronic lung diseases. Ann Am Thorac Soc. 2014;11(Suppl 3):S178–85. doi:10.1513/AnnalsATS.201312-443LD
   PubMedGoogle Scholar
• Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137(2):376–387. doi:10.1378/chest.09-1140
   PubMed Web of Science ®Google Scholar
• Burger CD, Ghandour M, Padmanabhan Menon D, Helmi H, Benza RL. Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes. Clinicoecon Outcomes Res. 2017;9:731–739. doi:10.2147/CEOR.S119117
   PubMed Web of Science ®Google Scholar
• Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618–3731. doi:10.1093/eurheartj/ehac237
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Channick R, De Marco T, et al. Results of an expert consensus survey on the treatment of Pulmonary Arterial Hypertension with oral prostacyclin pathway agents. Chest. 2020;157(4):955–965. doi:10.1016/j.chest.2019.10.043
   PubMed Web of Science ®Google Scholar
• American College of Cardiology. FDA approves selexipag for PAH patients. Available from: https://www.acc.org/latest-in-cardiology/articles/2015/12/22/11/39/fda-approves-selexipag-for-pah-patients/. Accessed May 17, 2024.
   Google Scholar
• de Lartigue J. Oral treprostinil for the treatment of pulmonary arterial hypertension. Drugs Today. 2014;50(8):557–565. doi:10.1358/dot.2014.50.8.2207312
   PubMed Web of Science ®Google Scholar
• Frost AE, Badesch DB, Miller DP, Benza RL, Meltzer LA, McGoon MD. Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis. Chest. 2013;144(5):1521–1529. doi:10.1378/chest.12-3023
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Hoeper MM, Channick RN, et al. Pulmonary arterial hypertension-related morbidity is prognostic for mortality. J Am Coll Cardiol. 2018;71(7):752–763. doi:10.1016/j.jacc.2017.12.010
   PubMed Web of Science ®Google Scholar
• Burger CD, Long PK, Shah MR, et al. Characterization of first-time hospitalizations in patients with newly diagnosed pulmonary arterial hypertension in the REVEAL registry. Chest. 2014;146(5):1263–1273. doi:10.1378/chest.14-0193
   PubMed Web of Science ®Google Scholar
• Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522–2533. doi:10.1056/NEJMoa1503184
   PubMed Web of Science ®Google Scholar
• White RJ, Jerjes-Sanchez C, Bohns Meyer GM, et al. Combination therapy with oral treprostinil for pulmonary arterial hypertension. A double-blind placebo-controlled clinical trial. Am J Respir Crit Care Med. 2020;201(6):707–717. doi:10.1164/rccm.201908-1640OC
   PubMed Web of Science ®Google Scholar
• Jing ZC, Parikh K, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013;127(5):624–633. doi:10.1161/CIRCULATIONAHA.112.124388
   PubMed Web of Science ®Google Scholar
• Tapson VF, Torres F, Kermeen F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest. 2012;142(6):1383–1390. doi:10.1378/chest.11-2212
   PubMed Web of Science ®Google Scholar
• Tapson VF, Jing ZC, Xu KF, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest. 2013;144(3):952–958. doi:10.1378/chest.12-2875
   PubMed Web of Science ®Google Scholar
• FDA. FDA label UPTRAVI. 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214275s000lbl.pdf. Accessed May 25, 2023.
   Google Scholar
• Gaine S, Sitbon O, Channick RN, et al. Relationship between time from diagnosis and morbidity/mortality in pulmonary arterial hypertension: results from the Phase III GRIPHON study. Chest. 2021;160(1):277–286. doi:10.1016/j.chest.2021.01.066
   PubMed Web of Science ®Google Scholar
• FDA. FDA label ORENITRAM; 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203496s011lbl.pdf. Accessed May 25, 2023.
   Google Scholar
• White RJ, Pepke-Zaba J, Balasubramanian VP, et al. Oral treprostinil treatment is associated with improved survival in pulmonary arterial hypertension participants in FREEDOM-EV and the FREEDOM-EV open-label extension study. Pulmon Vasc Dis. 2022;2022:1.
   Google Scholar
• Galie N, Gaine S, Channick R, et al. Long-term survival, safety and tolerability with selexipag in patients with pulmonary arterial hypertension: results from GRIPHON and its open-label extension. Adv Ther. 2022;39(1):796–810. doi:10.1007/s12325-021-01898-1
   PubMed Web of Science ®Google Scholar
• White R, Pepke-Zaba JP, Balasubramanian V, et al. Oral treprostinil treatment is associated with improved survival in pulmonary arterial hypertension participants in FREEDOM-EV and the FREEDOM-EV open-label extension study. Chest. 2022;162(4):A2301–A2303. doi:10.1016/j.chest.2022.08.1909
   Web of Science ®Google Scholar
• Coghlan JG, Galié N, Gaine S, et al. Long -term survival and safety with selexipag in patients with pulmonary arterial hypertension: results from the GRIPHON study and its open-label extension (id S122). BMJ J. 2018;2:1.
   Google Scholar
• Chin KM, Sitbon O, Doelberg M, et al. Three- versus two-drug therapy for patients with newly diagnosed pulmonary arterial hypertension. J Am Coll Cardiol. 2021;78(14):1393–1403. doi:10.1016/j.jacc.2021.07.057
   PubMed Web of Science ®Google Scholar
• McLaughlin V, Chin K, Farber H, et al. Clinical characteristics of patients with pulmonary arterial hypertension and treatment patterns: a real-world analysis from SPHERE (Selexipag: the Users Drug Registry). Chest. 2021;160(4):A2292–A2295. doi:10.1016/j.chest.2021.07.2001
   Google Scholar
• Park BD, Chin KM, Bartolome S Change in objective parameters after long-term selexipag therapy for pulmonary arterial hypertension: a single-center observational study. presented at: American Thoracic Society International Conference 2018; 2018.
   Google Scholar
• Sahay S, Ravichandran A, Parikh K, et al. Real-World transitions from parenteral, inhaled, and oral prostacyclin-class therapies to oral treprostinil: interim date from the ADAPT registry. presented at: American Thoracic Society International Conference Abstract; 2020.
   Google Scholar
• Kingrey J, Swisher J, Ravichandran A, et al. Interim data from the ADAPT registry: real-world tolerability and management of adverse events in patients receiving oral treprostinil. Chest. 2020;158(4):A2169–A2170. doi:10.1016/j.chest.2020.08.1864
   Web of Science ®Google Scholar
• Lange TJ, Soderberg S, Biedermann P, et al. Selexipag titration and dosing patterns in patients with pulmonary arterial hypertension (PAH) in a real-world clinical setting: insights from the EXPOSURE study. presented at: American Thoracic Society International Conference 2021; 2021.
   Google Scholar
• Corporation UT. The Orenitram Titration kit. Available from: https://www.orenitram.com/kit. Accessed April 22, 2023.
   Google Scholar
• Kim NH, Hemnes AR, Chakinala MM, et al. Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE. J Heart Lung Transplant. 2021;40(4):279–288. doi:10.1016/j.healun.2021.01.006
   PubMedGoogle Scholar
• Cui X, Lu W, Zhang D, et al. Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients. Front Cardiovasc Med. 2022;9:991586. doi:10.3389/fcvm.2022.991586
   PubMed Web of Science ®Google Scholar
• Song C, Kunovszki P, Beaudet A, et al. Comparison of healthcare encounters and drug persistence in patients with pulmonary arterial hypertension receiving oral selexipag, inhaled iloprost, or parenteral treprostinil: a retrospective database analysis. J Health Econ Outcomes Res. 2022;9(1):151–160. PMID: 35800882; PMCID: PMC9178228. doi:10.36469/001c.35246
   PubMedGoogle Scholar
• McLaughlin V, Kim NH, Hemnes AR et al. Selexipag dosing and titration in the first 500 patients enrolled in SPHERE (SelexiPag: tHe UsErs dRug rEgistry), European Heart Journal 2019;40(Supplement 1):ehz745.0526. doi:10.1093/eurheartj/ehz745.0526
   Google Scholar
• El-Kersh K, King C, Shen E, Classi P, Balasubramanian V. Contemporary dosing characteristics of oral treprostinil in real-world clinical practice in patients with pulmonary arterial hypertension. Chest. 2020;158(4):A2183–A2184. doi:10.1016/j.chest.2020.08.1873
   Web of Science ®Google Scholar
• Kung. Selexipag: real world data. presented at: CHEST annual meeting. San Antonio; 2012.
   Google Scholar
• Rahaghi FF, Feldman JP, Allen RP, et al. Recommendations for the use of oral treprostinil in clinical practice: a Delphi consensus project pulmonary circulation. Pulm Circ. 2017;7(1):167–174. doi:10.1086/690109
   PubMed Web of Science ®Google Scholar
• Chang S-A, Lee SH, Choi JH, et al. Real-world practice patterns and characteristics of adverse events with selexipag in Korean patients with pulmonary arterial hypertension; 2022.
   Google Scholar
• Highland KB, Hull M, Pruett J, Elliott C, Tsang Y, Drake W. Baseline history of patients using selexipag for pulmonary arterial hypertension. Ther Adv Respir Dis. 2019;13:1753466619843774. doi:10.1177/1753466619843774
   Web of Science ®Google Scholar
• Chin K, Chakinala M, Hemnes A, et al. Real-world data for selexipag in patients with connective tissue disease-associated pulmonary arterial hypertension: a SPHERE (Selexipag: the Users Drug Registry) Analysis. Chest. 2020;158(4):A2187–A2190. doi:10.1016/j.chest.2020.08.1875
   Web of Science ®Google Scholar
• Farber HW, Chakinala M, Highland KB, et al. Risk assessment at baseline and one year in patients with pulmonary arterial hypertension (PAH): data from the first 250 patients enrolled in SPHERE (Uptravi[Selexipag]: the users drug registry) (id A105). presented at: American Thoracic Society International Conference; 2019.
   Google Scholar
• Chin KM, Ruggiero R, Bartolome S, et al. Long-term therapy with oral treprostinil in pulmonary arterial hypertension failed to lead to improvement in important physiologic measures: results from a single center. Pulm Circ. 2015;5(3):513–520. doi:10.1086/682224
   PubMed Web of Science ®Google Scholar
• Ramani G, Cassady S, Shen E, et al. Novel dose-response analyses of treprostinil in pulmonary arterial hypertension and its effects on six-minute walk distance and hospitalizations. Pulm Circ. 2020;10(3):2045894020923956. doi:10.1177/2045894020923956
   Web of Science ®Google Scholar
• Balasubramanian VP, Messick CR, Broderick M, Nelsen AC. Dosing characteristics of oral treprostinil in real-world clinical practice. Pulm Circ. 2018;8(2):2045894018770654. doi:10.1177/2045894018770654
   Web of Science ®Google Scholar
• Lange TJ, Escribano P, Biedermann P, et al. Clinical characteristics and treatment patterns in patients with Pulmonary Arterial Hypertension (PAH) initiating selexipag in the EXPOSURE observational study. presented at: American Thoracic Society International Conference 2020; 2020.
   Google Scholar
• McConnell JW, Tsang Y, Pruett J, Drake W. Comparative effectiveness of oral prostacyclin pathway drugs on hospitalization in patients with pulmonary hypertension in the United States: a retrospective database analysis. Pulm Circ. 2020;10(4):2045894020911831. doi:10.1177/2045894020911831
   Web of Science ®Google Scholar
• Dean BB, Saundankar V, Stafkey-Mailey D, et al. Medication adherence and healthcare costs among patients with pulmonary arterial hypertension treated with oral prostacyclins: a retrospective cohort study. Drugs Real World Outcomes. 2020;7(3):229–239. doi:10.1007/s40801-020-00183-x
   PubMedGoogle Scholar
• Dean BB, Saundankar V, Stafkey-Mailey D, et al. Correction to: medication adherence and healthcare costs among patients with pulmonary arterial hypertension treated with oral prostacyclins: a retrospective cohort study. Drugs Real World Outcomes. 2020;7(3):241–242. doi:10.1007/s40801-020-00198-4
   PubMedGoogle Scholar
• Papademetriou E, Liu X, Beaudet A, Tsang Y, Potluri R, Panjabi S. Comparative evaluation of costs and healthcare resource utilization of oral selexipag versus inhaled treprostinil or oral treprostinil in patients with pulmonary arterial hypertension. J Med Econ. 2023;1–16. doi:10.1080/13696998.2023.2204769
   Web of Science ®Google Scholar